Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 14,500 shares, a decline of 68.0% from the March 31st total of 45,300 shares. Based on an average trading volume of 55,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.3% of the company’s stock are short sold.
Alzamend Neuro Stock Down 1.3 %
Shares of ALZN opened at $0.70 on Friday. The company has a 50 day moving average of $0.92 and a two-hundred day moving average of $1.23. Alzamend Neuro has a twelve month low of $0.65 and a twelve month high of $11.91. The company has a market cap of $4.81 million, a price-to-earnings ratio of -0.71 and a beta of 0.02.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.38) EPS for the quarter.
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Featured Articles
- Five stocks we like better than Alzamend Neuro
- What Are Dividend Champions? How to Invest in the Champions
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Choose Top Rated Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Energy and Oil Stocks Explained
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.